NICHD conducts and supports a variety of clinical research related to pregnancy. Select a link below to learn more about these projects.
- Pravastatin for Prevention of Preeclampsia
The purpose of this study is to determine the pharmacokinetic parameters and collect preliminary safety data for pravastatin when used as a prophylactic daily treatment in pregnant women at high risk for preeclampsia.
- A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)
The purpose of this Maternal-Fetal Medicine Units Network study is to determine whether treating pregnant women who have a primary CMV infection with CMV antibiotics will reduce the number of babies infected with CMV.
- A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation with a Short Cervix (PROSPECT)
This Maternal Fetal Medicine Units Network trial aims to determine whether the n pessary or vaginal progesterone reduce the risk of preterm birth in women with a short cervix and twin gestation.
- Antimalarial Pharmacology in Children and Pregnant Women in Uganda
This study will determine if the use of anti-HIV medications will affect the pharmacokinetic exposure of antimalarial medications during the treatment for uncomplicated malaria in HIV-infected children and pregnant women, and evaluate the impact of age and pregnancy on this exposure.
- Folic Acid and Zinc Supplementation Trial (FAZST)
This study seeks to determine whether zinc and folic acid diet supplementation, compared to placebo, will improve semen quality and affect live birth rates among 2,400 couples who are attempting to conceive and seeking assisted reproduction at participating clinics.
- Establishment of a Perinatal Database and a Bank of Biological Materials
This project will establish a large clinical database and a bank of biological materials intended for use in improving the pathophysiological understanding of mechanisms underlying various pregnancy diseases. Clinical data will be taken from medical records and the associated biological samples will include maternal blood, umbilical cord plasma, amniotic fluid, maternal urine, and placental tissue.
- Material Newborn Health Registry (MNH)
This study will enroll 60,000 pregnant women and the infants from their pregnancy from 12 locations worldwide. Its purpose is to quantify and understand the trends in pregnancy outcomes over time in order to provide population-based data on stillbirths and neonatal and maternal mortality.
- Placenta Imaging Project (PIP)
This study intends to enroll 300 pregnant women, divided into three groups of 60 low-risk non-smokers, 90 smokers, and 150 high-risk non-smokers, to validate and establish the utility of placental MRI at 16, 24, and 32 weeks gestation for identifying the risk of adverse clinical outcomes. MRI data will be combined with placental tissue collected at infant delivery.
Information on current NIH-sponsored clinical trials is available by following the link below or by calling 800-411-1222.